Airsculpt Technologies, Inc. · NASDAQ:AIRS
Airsculpt Technologies — Investor Presentation (August 2026)
19 slides from Airsculpt Technologies's investor presentation, August 2026
Slide 1: Investor Presentation
Investor Presentation August 2026
Slide 2: Disclaimer
Disclaimer General Disclaimer This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities AirSculpt Technologies, Inc. (the “Company”), nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale wo
Slide 3: Differentiated disruptor in the body contouring market
A differentiated disruptor in the body contouring market with a proven, surgeon-led model positioned to capitalize on a large, underpenetrated market with a long runway for profitable growth. 31 $151M - $157M CENTERS 2026 REVENUE GUIDANCE 350+ $12M - $14M EMPLOYEES 2026 EBITDA GUIDANCE ~12,000+ ~60%
Slide 4: What is AirSculpt? How is it Different?
What is AirSculpt®? How is it Different? AirSculpt is a premium provider of body Minimally invasive procedure delivered in one sculpting procedures session – no scalpel, stiches or general anesthesia Dramatic, fast, natural-looking results – can permanently remove up to 10 pounds of fat(1) and tight
Slide 5: Key Investment Highlights
Key Investment Highlights 1 Proven Business Model with Foundation to Deliver Profitable Growth 2 Three main growth levers driving path to accelerated revenue growth - Enhanced marketing and sales strategy to drive stabilization - Expansion in Service Offering to Capture GLP-1 Opportunity - Denovo gr
Slide 6: Attractive Business Model Stabilized & Positioned for Growth
Attractive Business Model Stabilized & Positioned for Growth Attractive Center Economics Consistent Revenue per Case Improving Performance • Metropolitan, high-end retail • Ongoing innovation sustaining • Sequential same-center sales locations driving consistent patient ~$12,000–$13,000 average reve
Slide 7: Same-Center Sales Recovery
Same-Center Sales Recovery Same-center sales improved from (23%) in 1H25 to approximately flat year-to-date Q1 '25 Q2 '25 Q3 '25 Dec '25 1H’ 26 Q1 Average Q2 Average Q3 Average Year-End Exit YTD Same-center sales: Approximately Flat -24% -22% -20% (msd%) Same-center case volumes: +1% Improving trend
Slide 8: Business Stabilization in 2026 after years of Transformation
Business Stabilization in 2026 after years of Transformation Total Revenue ($MM) Adj. EBITDA ($MM)2 ($ in millions) Strong Growth Through 2023 Transformation Stabilization4 Strong Growth Through 2021 Transformation Stabilization3 $250 $50 $46 $43 $43 $196 $200 $180 $40 $169 $152 $151-157 $150 $133 $
Slide 9: Summary of Growth Levers
Summary of Growth Levers Three key levers driving AirSculpt's path to accelerated revenue growth 1 2 3 Enhanced GLP-1 Opportunity & De Novo Marketing Strategy Expanded Services Growth Driving higher patient volume through refined Capturing the massive wave of post-GLP-1 Expanding AirSculpt's geograp
Slide 10: Amplifying the AirSculpt brand
Enhanced Marketing Strategy FIVE KEY PRIORITIES Optimizing spend toward higher-value 1 Amplifying the audiences AirSculpt brand 2 Onboarding new PR and marketing agencies Launching campaigns for skin tightening 3 and skin excision We are sharpening our messaging, targeting spend towards high-intent
Slide 11: GLP-1 Drugs Driving a Structural Shift in Body Contouring Demand
GLP-1 Drugs Driving a Structural Shift in Body Contouring Demand AirSculpt's proprietary body contouring uniquely addresses the new needs of GLP-1 patients Look as Good as You Feel GLP-1 Users 1 Stubborn Fat Removal 2023 5M • GLP-1 patients lose significant weight but often retain stubborn, localize
Slide 12: Expanding Services to Serve Growing Consumer Demand
Expanding Services to Serve Growing Consumer Demand CURRENT OFFERINGS Fat Removal & Fat Transfer AirSculpt+ Largest fat transfer provider in the industry. ~20% of procedures Enhanced skin tightening using Apyx Medical – Renuvion in include a fat transfer. Areas include buttocks, breast, hip, and han
Slide 13: Large Potential White Space Opportunity for De Novo Expansion
Large Potential White Space Opportunity for De Novo Expansion AirSculpt Has Significant White Space Opportunity +350 – 550 +150 – 250 International Centers +200 – 300 U.S. / Canada 31 Centers Current Potential White Additional De Novo Center Opportunities Space Strong demand for body sculpting servi
Slide 14: Strengthened Balance Sheet
Strengthened Balance Sheet Reduced Debt by ~$30M Since the Start of 2025, with ~$24M of Available Liquidity2 ($ in millions) $75 $75 $69 $64 $64 $60 $58 $57 Reduced Leverage1 1 $52 Below 2.5x Leverage Ratio $48 • Net Debt to EBITDA below 2.5x, creating greater $46 $44 financial flexibility $29 $25 ~
Slide 15: Commitment to Operational Excellence
Commitment to Operational Excellence AirSculpt has strengthened its leadership team and streamlined operations to drive operational excellence Refreshed Executive Talent 1 New CFO, President of Operations, General Counsel • Deepened the bench by adding a new CFO, President of Operations, & General C
Slide 16: Significant Progress Against Key Business Priorities
Significant Progress Against Key Business Priorities Business priorities and progress reported across key strategic initiatives Business Priorities Progress Reported 1 Enhancing our sales & marketing strategy Optimized sales and marketing execution to drive higher-quality leads Introducing new servi
Slide 17: Why AirSculpt
WHY AIRSCULPT • Efficacious patented method with a proven track record of performing body contouring procedures • Achieved critical mass with significant runway for growth • Strong return on investment with positive cash flow generation across U.S. centers • Incentivized management team with deep ex
Slide 18: Appendix
- Appendix - - Appendix - 18
Slide 19: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation ($ in thousands) 2019 2020 2021 2022 2023 2024 2025 Net income (loss) $ (2,212) $ 7,577 $ 10,551 $ (14,679) $ (4,240) $ (8,018) $ (11,667) Plus Sponsor management fee 500 500 1,636 - - - - Equity-based compensation 341 325 7,185 29,457 18,224 3,762 2,331 Loss on debt m
AirSculpt Technologies — Investor Presentation (August 2026) on 6ix